Structure basis for inhibition of SARS-CoV-2 by the feline drug GC376.

Authors:
Luan XD; Chen BX; Shang WJ; Yin WC; Jin Y and 3 more

Journal:
Acta Pharmacol Sin

Publication Year: 2022

DOI:
10.1038/s41401-022-00929-z

PMCID:
PMC9243920

PMID:
35773339

Journal Information

Full Title: Acta Pharmacol Sin

Abbreviation: Acta Pharmacol Sin

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Competing interests The authors declare no competing interests."

Evidence found in paper:

"This work was supported by Beijing Natural Science Foundation (M21016 to SZ); CAMS Innovation Fund for Medical Sciences (2021-I2M-1-003 to SZ); CAMS Innovation Fund for Medical Sciences (2021-CAMS-JZ004 to SZ); Tsinghua University-Peking University Center for Life Sciences (045-61020100122 to SYZ) and Institute of biomedicine, Tsinghua University. We thank the assistance of Protein Preparation and Identification Facility at Technology Center for Protein Science of Tsinghua University. We appreciate the help from Genscript Biotech Co. Ltd for DNA synthesis, Vazyme Biotech Co. Ltd for offering ClonExpress II One Step Cloning Kit, NEST Biotechnology Co. Ltd for offering centrifugal tube and Topscience for offering GC376."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025